How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Zirabev is given by a doctor or nurse, not picked up at a pharmacy.

What to do

  1. Ask your care team or your plan what you’d pay before your visit.

Your care team and your insurance decide which product you get.

Compare every option

Brand name

Zirabev, the original

Cash priceAsk the pharmacy
Ways to save on Zirabev

The maker’s card

Pfizer Oncology Together Co-Pay Savings Program for Injectables

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

The card takes up to $25,000 a year off your co-pay.

Sign up on pfizercopay.com 

Or call 1-800-555-4820.

In the maker’s words

“as little as $0 per administered dose.”

From the maker’s offer on pfizercopay.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

Zirabev is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Not soldAsk the pharmacy

What it’s used for

What the FDA label says

ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of:

  • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
  • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.

Limitations of Use: ZIRABEV is not indicated for adjuvant treatment of colon cancer.

  • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
  • Recurrent glioblastoma in adults.
  • Metastatic renal cell carcinoma in combination with interferon alfa.
  • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer:
    • oin combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, for stage III or IV disease following initial surgical resection.
    • oin combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
    • oin combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by ZIRABEV as a single agent, for platinum-sensitive recurrent disease.

Source: the FDA label for Zirabev (Pfizer Laboratories Div Pfizer Inc), July 21, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.